Micronized progesterone: clinical indications and comparison with current treatments.
OBJECTIVE
To integrate and evaluate the pharmacokinetic, endocrine, and clinical effects of micronized progesterone formulations.


METHODS
Published articles concerning the pharmacokinetics of orally administered progesterone and the potential clinical uses of oral micronized progesterone were reviewed. Results concerning their use for secondary amenorrhea, premenopausal bleeding disorders, luteal phase dysfunction, termination of premature labor, hormone replacement therapy, and premenopausal syndrome are summarized. Critical issues to be resolved through ongoing preclinical and clinical research are highlighted.


RESULTS
Because of the enhanced bioavailability of oral micronized progesterone, the compound may be useful for a variety of therapeutic indications. Oral micronized progesterone is available in France, and a formulation recently has been approved in the United States for the treatment of secondary amenorrhea and postmenopausal hormone replacement therapy. A large body of evidence, including the Postmenopausal Estrogen/Progestin Interventions study, suggests that the use of a combination of estrogen and oral micronized progesterone is optimal for long-term hormone replacement therapy. There also are data indicating that oral micronized progesterone could be of potential use for the treatment of premenopausal bleeding disorders, luteal phase disorders, and premature labor.


CONCLUSIONS
Oral micronized progesterone has widespread clinical potential, particularly for the treatment of secondary amenorrhea and dysfunctional premenopausal bleeding, and as a component of postmenopausal hormone replacement therapy.
Fitzpatrick
L A
LA
Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Good
A
A
D000568:Amenorrhea / Q000188:drug therapy; D001682:Biological Availability; D004304:Dosage Forms; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D007247:Infertility, Female / Q000628:therapy; D008599:Menstruation Disturbances / Q000188:drug therapy; D011247:Pregnancy; D011374:Progesterone / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use
D004304:Dosage Forms; D011374:Progesterone